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Abstract: Many studies have evidenced the main role of lipids in physiological and also 
pathological processes such as cancer, diabetes or neurodegenerative diseases. The 
identification and the in situ localization of specific low-abundant lipid species involved in 
cancer biology are still challenging for both fundamental studies and lipid marker 
discovery. In this paper, we report the identification and the localization of specific 
isobaric minor phospholipids in human breast cancer xenografts by FTICR MALDI 
imaging supported by histochemistry. These potential candidates can be further confirmed 
by liquid chromatography coupled with electrospray mass spectrometry (LC-ESI-MS) after 
extraction from the region of interest defined by MALDI imaging. Finally, this study 
highlights the importance of characterizing the heterogeneous distribution of low-abundant 
lipid species, relevant in complex histological samples for biological purposes. 
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1. Introduction 
The lipid family is composed of a wide range of molecular species that include triacylglycerides, 
sphingolipids, phosphoglycerides and sterols [1]. They are involved in physiological processes 
regulated by thousands of metabolic pathways (e.g., fusion/division [2,3] or apoptosis [4], cell shape [3], 
membrane vesicle trafficking [5], signal transduction [6]). Alterations of these pathways are associated 
with a variety of human diseases such as cancer [7], neurodegenerative diseases [8,9], heart disease [10,11] 
or diabetes [12]. 
As for genomics and proteomics that aim at studying genes and proteins respectively, tools have 
been developed in the field of lipidomics for a comprehensive exploration of lipids [13]. The detection 
and localization of biomolecules are generally performed by chemical imaging techniques such as dye 
staining and immunohistochemistry. However, common lipid stainings which target neutral lipids [14–17] 
are limited to the study of a few lipids in tissues. Moreover, when immunohistochemical methods are 
employed, the use of antibodies raised against different phospholipid head groups does not allow the 
individual localization of specific lipid molecular species in tissues. Consequently, a powerful method 
for the direct localization and characterization of lipids would bring a significant advance to the field. 
To identify lipids, spectroscopic methods including nuclear magnetic resonance spectroscopy, 
fluorescence spectroscopy, as well as mass spectrometry (MS) have been used and coupled with 
separation methods [18,19]. However, this requires the preliminary extraction of the lipids and result 
in the loss of localization information. Improvements in mass spectrometry have led to an 
unprecedented capacity to characterize lipid species directly on tissue sections or after extraction.   
For instance, matrix-assisted laser desorption/ionization mass spectrometry imaging (MALDI MSI) is 
an emerging application for lipid research and has been applied for the in situ identification and 
localization of membrane lipids on tissue sections of lung [20], brain [21] and kidney [22] without the 
requirement of specific probes or staining. Liquid chromatography (LC) separation coupled with 
electrospray ionization (ESI) mass spectrometry has been used for the analysis of complex mixtures [23]. 
Many lipid species share similar m/z  ratios and only the most abundant are generally   
detected [7,8,10–12,24] but the minor ones could also be relevant for physiological and pathological 
processes [25]. The use of very high mass resolution and accurate mass determination for MALDI MSI 
and LC-ESI-MS analyses allows resolving near isobaric lipid species for the detection of individual 
classes of phospholipids in a narrow mass range [19,26,27]. Moreover the high sensitivity and 
excellent (low) limit of detection of these types of techniques render possible the analysis of   Int. J. Mol. Sci. 2013, 14 24562 
 
less-abundant lipids. These ones are indeed potential lipid markers of a disease and are quite difficult 
to be characterized in highly complex mixture [26]. 
In this study, high resolution mass spectrometry MALDI MSI coupled to histochemistry was used 
to localize and identify minor lipid species and further characterization was achieved by LC-ESI-MS 
(Figure 1). First, a MALDI MSI image of lipids was acquired in broadband detection mode and minor 
lipid species were selected to analyze tumor heterogeneity according to regions of interest associated 
with specific biological processes such as proliferating tumor area, necrosis, and inflammatory process 
on xenografts of human breast cancer cells, either highly invasive (MDA-MB-435 and MDA-MB-231 
cells) or poorly aggressive (MCF-7 cells). The MALDI MSI analysis was then performed using the 
narrowband detection mode at higher mass resolution, in order to discriminate lipids with close 
masses. The high mass accuracy allowed the determination of their molecular formula by exact mass 
measurements. In the final step, LC-ESI-MS analysis was used to characterize the suspected 
phospholipids (PLs) from lipid extracts. We herein provide evidence for the suitability of this highly 
sensitive MSI based on molecular histology for the analysis of low-abundant PL species in different 
microenvironmental tumor regions of biological interest in human breast tumor xenografts. 
Figure 1. General workflow for the characterization by LC-ESI-MS guided by MALDI 
MSI of low-abundant lipids in tissue using FTICR mass spectrometry. (1) Large scale lipid 
analysis by MALDI MSI to target lipids of biological relevance after comparison with 
histochemical staining; (2) Targeted MALDI MSI analysis and molecular formula 
determination by exact mass measurement; and (3) LC-ESI-MS analyses for the 
characterization of low-abundant PL classes from lipid extracts. 
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2. Results and Discussion 
2.1. In Situ Analysis by MALDI-FTICR MSI and Immunohistochemistry Reveal Specific Low-Abundant 
Lipid Species and Breast Tumor Heterogeneity 
In order to investigate all lipid classes, tumor sections obtained from tumor xenografts of three 
different human breast cancer cell lines were firstly analyzed by MALDI MSI in a mass range 
comprised between m/z 100 and 1500. Results of Figures 2A and S1 correspond to the average mass 
spectrum obtained from the simultaneous analysis of sections of tumors derived from MCF-7,   
MDA-MB-231 and MDA-MB-435 cells. As shown in previous studies, the use of the 1,5-DAN matrix 
on tissue sections has proven efficacy for providing rich lipid signatures for MALDI MSI analysis in 
both negative and positive polarity with no analyte delocalization [28,29]. Data presented in   
Figures 2A and S1 show a typical MALDI-MSI lipid profile with peaks of high intensity characteristic 
of the different phospholipid (PL) species (between m/z 700 and 800) [30]. Most of these PLs belong 
to the phosphatidylcholine (PC) and phosphatidylethanolamine (PE) classes that are the most abundant 
PLs in mammalian cell membranes (40%–50% of total PLs for PC and 20%–50% for PE) [31]. The 
regulation of these PL species, notably in cellular membrane, has been associated with apoptosis [32], 
malignant transformation [33] and oxidative process [34]. In addition to the most abundant PC and PE 
detected, peaks with signal intensity barely detectable above the noise level are present and were 
considered for lipid mapping (Tables 1 and 2 and examples in insets of Figures 2A and S1). 
We then performed targeted MALDI MSI experiments of each tumor sections to focus on PL 
analysis. Ion images for m/z  values of 703.5728, 705.5907, 744.5901, 754.5366, and 796.6218 
revealed that numerous low-abundant PLs display a specific distribution within each section   
(as exemplified for MDA-MB-435 tumor section, Figure 2B). As shown in the left panels of   
Figures 3A and S2A, ion images (overlays of three ion images) fit with the general histological 
features revealed by H&E staining (right panels of Figures 3A and S2A for MDA-MB-435 and MCF-7 
tumor sections, respectively). To determine if each minor PL is associated with different tumor 
compartments, we faced MALDI MSI ion images with binary images displaying three different 
immunostainings (CD45 positive inflammatory cells, Ki-67 positive proliferating human tumor cells 
and carbonic anhydrase IX positive corresponding to hypoxic areas) (Figure 3B,C for MDA-MB-435 
and S2B for MCF-7 tumor section). In this way, we were able to confirm the biological relevance of 
the PLs that display a specific biological distribution in the areas of proliferating human tumor cells 
(m/z values of 706.5379), the hypoxia (m/z values of 744.5901, 754.5366, and 796.6218) and 
inflammation (m/z values of 703.5728 and 705.5907). Notably, such specific spatial distribution is not 
observed for other PLs present in the whole tissue section (as example PLs with an m/z value of 
758.5703 and 760.5849, Figure S3). Additional illustrative examples of low-abundant PL species 
specifically associated with one or two/three tumor compartments are listed in Tables 1 and 2, respectively. 
We herein demonstrate the suitability of PL identification to identify and/or delineate the different 
compartments composing the complex tumor ecosystem and which are known to influence the 
evolution of cancer and their response to therapeutic agents. The involvement of phospholipids in 
inflammatory processes, including their use by macrophages has already been reported [35]. 
Furthermore, oxidized PLs (oxPLs) are abundantly found at sites of inflammation and are considered Int. J. Mol. Sci. 2013, 14 24564 
 
to play an active role in the modulation of the immune response [36]. The relationship between   
active oxygen species, lipid peroxidation and necrosis has been highly demonstrated in many 
pathological processes [37–39]. 
Figure 2. Large scale lipid analysis by MALDI MSI for low-abundant lipids of biological 
relevance targeting. (A) Broadband average mass spectrum of a simultaneous MALDI MSI 
analysis on sections of tumors derived from MCF-7, MDA-MB-231, and MDA-MB-435 
cells. Inset indicates molecular species in a mass range comprised between m/z 744.44 and 
744.64 considered for lipid mapping; and (B) MALDI MSI ion image representing the 
repartition of five low-abundant PLs (m/z 703.5728, m/z 705.5907, m/z 744.5901,   
m/z 754.5366 and m/z 796.6218) in a MDA-MB-435 tissue section (scale bars, 2 mm). 
 
Tumor hypoxia is an important factor influencing malignant progression and tumor cell sensitivity 
to radio- or chemotherapy treatment. Actually, a few markers of hypoxic zones such as carbonic 
anhydrase IX, glucose transporter-1 (GLUT-1) or HIF1α are available [40,41]. Consequently, a 
method that provides a highly sensitive MSI-based analysis of low-abundant PL species for 
concomitant detection and analysis of hypoxic areas and the surrounding tumor cells opens new 
perspectives for studying the tumor adaptation to hypoxic conditions and to predict their response  
to treatment. Int. J. Mol. Sci. 2013, 14 24565 
 
Figure 3. Determination of low-abundant PL species associated with different tumor 
compartments by correlation between MALDI MSI data and histochemical stainings.   
(A) MALDI MSI ion image representing the localization of three PLs (m/z values of 
703.5728 in red, 706.5379 in blue, and 744.5901 in green) in a section of tumor induced by 
MDA-MB-435 cells (right panel) and hematoxylin/eosin staining (left panel). Dotted lines 
on the hematoxylin/eosin stained section image delineate necrosis “N” and tumor “T” 
areas; (B) Binary images of CD45 (left panel), Ki-67 (central panel) and CA IX   
(right panel) immunostainings of MDA-MB-435 serial tissue sections. Dotted lines of each 
binary image delineate the localization of PL (1) (m/z 703.5728 in red); PL (2)  
(m/z 706.5379 in blue) and PL (3) (m/z 744.5901 in green) shown in ion image. Squares 
indicate positions of high magnification microscopy images of immunohistochemistry (C);  
and (C) High magnification microscopy images of immunohistochemistry for CD45 (left),  
Ki-67 (middle) and CA IX (right) immunostainings (scale bars, 500 μm). 
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Table 1. Low-abundant PL species associated with one specific tumor area detected during 
MALDI MSI analyses. Grey highlighted (+) corresponds to the localization of the   
PL species in tissues. 
m/zobs Necrosis Inflammation Tumor
703.5728  −  +  − 
705.5821  +  −  − 
706.5379  −  −  + 
718.5748  +  −  − 
720.5812  +  −  − 
725.5574  +  −  − 
728.5197  −  +  − 
739.4666  −  −  + 
740.4714  −  −  + 
740.4993  −  −  + 
740.5207  +  −  − 
740.5573  +  −  − 
741.5311  −  −  + 
744.5512  −  −  + 
744.5901  +  −  − 
765.4836  −  −  + 
768.5901  +  −  − 
770.5107  −  −  + 
772.5248  −  −  + 
772.6217  +  −  − 
774.6378  +  −  − 
790.5098  −  −  + 
790.5742  +  −  − 
796.5252  −  −  + 
796.5854  −  +  − 
796.6218  +  −  − 
798.5416  −  −  + 
Table 2. Low-abundant PL species associated with two or three specific tumor areas 
detected during MALDI MSI analyses. Grey highlighted (+) corresponds to the 
localization of the PL species in tissues. 
m/zobs Necrosis Inflammation Tumor
704.5221  −  +  + 
705.5904  +  −  + 
720.5542  −  +  + 
723.4943  +  −  + 
730.5384  −  +  + 
731.6066  +  +  + 
734.5693  −  +  + 
746.5698  +  +  + 
746.6065  +  −  + Int. J. Mol. Sci. 2013, 14 24567 
 
Table 2. Cont. 
m/zobs Necrosis Inflammation Tumor
754.5364  +  +  + 
772.5847  +  +  + 
784.5725  +  +  − 
784.5853  −  +  + 
790.5419  +  +  − 
794.6049  +  +  − 
2.2. Use of High-Resolution Mass Spectrometry for the Identification of Minor Lipid Species with 
Biological Relevance 
One of the main current issues in lipidomics is the accurate detection and localization of minor  
PL species with near isobaric masses. We herein demonstrate that one way of tackling this problem is 
the use of FTICR mass spectrometers with a suitable mass resolution to detect two or more   
(low-abundant) PLs within a very tight mass range. Our result indicates that in addition to the peak 
corresponding to a PL with an m/z value of 744.59019 (Figures 2B and 4, peak 3), two supplementary 
peaks were detected in a mass range that does not exceed 0.2 Th (e.g., m/z values of 744.49419, peak 1 
and 744.55385, peak 2) (Figure 4). Other peaks with low m/z differences were also detected and 
another example is shown in Figure S4 (m/z values of 796.52524, peak 1; 796.58547, peak 2 and 
796.62181, peak 3). Interestingly, the relative intensities of these peaks were reproducible between 
three biological replicates and define patterns that can be associated with the tumor type and/or the 
invasiveness (MCF7 versus MDA-MB-231 and MDA-MB-435 tumors) [arrows in Figure S5 for   
m/z 744.45 to 744.60 (A), m/z 796.50 and 796.65 (B), m/z 790.50 and 790.58 (C)]. Using probabilistic 
Latent Semantic Analysis (pLSA), we were able to confirm indirectly these specific patterns by 
visualizing the discriminating peaks between MCF7 versus MDA-MB-231 (Figure S6A) and MCF7 
versus MDA-MB-435 tumors (Figure S6B). This result is in agreement with a recent study showing 
that the relative abundance of PCs varies according to the degree of differentiation and metastatic 
potential in breast cancer cells [42]. Studies have also evidenced that PL cell content can change in 
murine mammary tumor cells and human cancer [43,44] and is due to an enhanced cell membrane 
synthesis depending on cell growth phase, cell type and malignancy [45]. For PC and PE, variations 
are predominantly observed during the G1 phase and this is due to a higher activity of the enzymes 
controlling their metabolism [46]. The presence of different PL patterns was also reported in biological 
models of primary human fibroblasts and macrophages [47]. Ion images of Figures 4 and S4 are in 
good agreement with this last study since each PL is differently distributed on MDA-MB-435 and 
MCF-7 tissue sections. 
The identification of these PL species was carried out by database matching using Lipid Maps 
database. The high mass accuracy measurement enabled the determination of the elemental 
composition of these biomolecules with accuracy better than 0.5 ppm (Tables 3 and 4). However, the 
high number of PL species sharing the same elemental composition did not allow their univocal 
identification and, as listed in Tables S1 and S2, several PCs or PEs were identified at the same 
molecular mass. This warrants caution on minor PL identification based on elemental formulas. Int. J. Mol. Sci. 2013, 14 24568 
 
Figure 4. MALDI MSI analyses of MCF-7 (to the left) and MDA-MB-435 (to the right) 
tumor sections in narrowband mode. Associated ion images represent the localization of 
low-abundant PLs with m/z  744.49419 (peak 1), m/z 744.55385 (peak 2) and m/z 
744.59019 (peak 3). PL relative contents determined by LC-ESI-MS are available in Table S3 
(scale bars, 1 mm). 
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Table 3. Elemental formulas of minor PL species (m/z 744.49419, 744.55385, and 
744.59019) detected during MALDI MSI analyses. 
m/zobs Elemental  formula 
1  m/zth Error  (ppm) 
744.49419 C38H76NO8P ([M + K]
+)
  744.49401 0.24 
744.55385 C41H79NO8P ([M + H]
+) 744.55378  0.09 
744.59019 C42H83NO7P ([M + H]
+) 744.59017  0.04 
1 Elemental formula of protonated ([M + H]
+) and adducted ([M + K]
+) ion species. 
Table 4. Elemental formulas of minor PL species (m/z 796.52524, 796.58547, and 
796.62181) detected during MALDI MSI analyses. 
m/zobs Molecular  formula 
1  m/zth Error  (ppm) 
796.52524 C42H80NO8P ([M + K]
+) 796.52531  0.1 
796.58547 C45H83NO8P ([M + H]
+) 796.58508  0.5 
796.62181 C46H87NO7P ([M + H]
+) 796.62147  0.4 
1 Elemental formulas of protonated ([M + H]
+) and adducted ([M + K]
+) ion species. 
2.3. Targeted Characterization of Specific Low-Abundant Phospholipid Species in Complex Mixtures 
by LC-ESI-MS 
Due to the dynamic behavior of cells, their exact lipid content is difficult to assess. Numerous 
metabolic pathways tightly regulate the lipid biosynthesis and turnover [48] and, even with a FTICR 
mass spectrometer, minor PL species cannot be directly identified by MALDI-MSI (Tables S1 and S2). 
As previously shown, the development of a method for their analysis remains a challenge [19].   Int. J. Mol. Sci. 2013, 14 24569 
 
LC-ESI-MS has proven to be a multidimensional approach with good sensitivity for the study of  
high-abundant lipids, especially PLs [49,50]. 
To reduce the list of the potential candidates identified during MALDI MSI analyses, a hybrid 
linear ion trap/FTICR mass spectrometer was used for PL characterization by LC-ESI-MS.   
PL screenings were performed on complex total lipid extracts from MDA-MB-435 or MCF-7 
xenografts using reverse phase high performance liquid chromatography. The separation of the 
isobaric species based on their different hydrophobic behavior allowed the characterization from 
complex samples of the lipid class of each minor PL analyzed by MALDI MSI (Figures 4 and S4). 
Assuming that the extraction methods and quantification of PL using the LC-ESI-MS method [51] is 
representative of the composition of the original PLs of the tissue (confirmed in Figure S7 for ions 
presented in Table 3), low-abundant PLs detected during MALDI FTICR MSI analyses were 
investigated by a targeted LC-ESI-MS screening (Figures 5A and S8A). The LC-ESI-MS extract ion 
currents (m/z ranges 744 to 745 and 796 to 797) are given in insets of Figures 5A and S8A. In this 
mass range, several chromatographic peaks associated to lipid species were revealed in each tissue. 
The exact mass measurements acquired with the FTICR analyzer allowed the assignment of the same 
PL species previously observed during MALDI MSI experiments (Figures 5B–D and S8B–D). All the 
isobaric PL species presented in Figures 4 and S4 were then characterized by MS/MS at respective 
retention times (insets of Figures 5B–D and S8–D). Collision induced dissociation of PC- and   
PE-derived [M + H]
+ ions typically yield major product ions at m/z 184 or loss of 141   
Th corresponding to the PE and PC polar headgroups, respectively [52]. Note that we roughly used a 
similar method for lipid identification as that from the recent paper from Kind et al., except that we did 
not build any database for assisted identification using the NIST MS Search Program [53]. Elution 
time of lipids allowed the confirmation of the elemental composition of each PL of Tables 3 and 4 with 
regards to Na and K adducts. Moreover, ionic suppressive effects can be observed between PC and PE 
according to the matrix used during MALDI MSI analysis (data not shown). Due to the separation of 
PLs by LC-ESI-MS, interferences are not co-eluted with compounds of interest and avoid the 
suppression of ionization that usually occurs during the MALDI process [54,55]. The relative 
abundance of PL species can be assessed during LC-MS experiments. Nonetheless, the absolute 
quantification and unambiguous identification of PLs could be ensured using the appropriate internal 
standards. Thus, the use of LC-ESI-MS is mandatory to discriminate between high- and low PL 
species. The identification of PL species on the basis of the exact mass measurement during   
MALDI MSI did not reach the highest confidence level for the full characterization of PL species. 
Efficient ionization by LC-ESI-MS, using tandem MS (e.g., ion trap), high mass resolution and 
accurate mass analyzer (i.e., FTICR or Orbitrap) allied to MS spectra obtained in parallel with   
MALDI MSI allowed the assignation of the sub-class of minor isobaric PLs on the basis of the 
identified head group by MS/MS (Tables S1 and S2). These data provide a proof-of-concept for the 
suitability of high resolution MS associated to immunohistochemical analysis to identify and localize 
low-abundant lipid species. In perspective, the use of appropriate (internal) standards will lead to the 
complete and unambiguous characterization of lipid isomers identified by LC-MS guided by high 
resolution MALDI imaging. Int. J. Mol. Sci. 2013, 14 24570 
 
Figure 5. LC-ESI-MS analyses of lipid extracts from MCF-7 and MDA-MB-435 tissues. 
(A) Total ion currents (TIC) of LC-ESI-MS analyses. Insets show the extract ion currents 
ranging from m/z 744 to 745; and (B)–(D): Exact mass measurements acquired with the 
FTICR analyzer. Insets show MS/MS spectra at respective retention times. The 
visualization of an ion at m/z 184 indicates that the PL is a PC. Neutral loss fragment of 
141 Da indicates that the PL is a PE. 
 
Breast cancer progression and metastatic dissemination is determined by the heterogeneity of both 
intrinsic breast cancer cell features and extreme factors related to the tumor microenvironments [56]. 
Among microenvironmental factors, oxygenation status (hypoxia and normoxia) and the recruitment of 
host cells including inflammatory, vascular cells or stroma cells are determinant. This complex 
tumoral ecosystem contributes to tumor sensitivity to radio- or chemotherapy and to the selection of 
aggressive tumor clones with metastatic potential. The heterogeneous nature of the tumor is 
highlighted in the present work by the detection of low-abundant PL species specifically associated 
with different tumor microenvironments. We observed a gradient of minor PL species from the center 
of the necrotic area to the proliferating tumor region (Figure S9) but none of the major PLs shared a 
similar distribution (as exemplified in Figure S3). This finding underlines the usefulness of developing 
high resolution MS methods to detect, separate and identify low-abundant PL species; potential 
markers of metabolic reprogrammation or regulators of malignant feature. A better molecular 
characterization of the different tumor compartments and of the tumor-host interface is mandatory to 
improve our understanding of complex biological processes occurring inside tumors, and to unravel 
molecular mechanisms associated with radio and/or chemo-resistance. In addition, cartography of   
low-abundant PL distribution among tumors will be helpful to investigate the metabolism of tumors, 
recently proposed by Hanahan et al. as a novel hallmark of cancer [57]. Int. J. Mol. Sci. 2013, 14 24571 
 
3. Experimental Section 
3.1. Reagents 
Purified matrix 1,5-diaminonaphtalene (1,5-DAN) was purchased from Sigma-Aldrich, Saint Louis, 
MO, USA. For LC-MS experiments, all chemicals were purchased from Sigma-Aldrich except   
ultra-pure water. Highly pure water of 18.2 MΩ-cm purity was produced using a Q-gard 1 purification 
pack (Millipore, Molsheim, France). Glass and polypropylene vials of 2 mL and 200 μL were 
purchased from VWR (VWR, Leuven, Belgium). For LC-ESI-MS experiments, the mobile phases 
were (A) 10 mM of ammonium acetate and 1 mM of acetic acid dissolved in 40% methanol and  
(B) 10 mM of ammonium acetate and 1 mM of acetic acid dissolved in 59.5% of isopropanol and 
39.5% of methanol. Buffers (A) and (B) were freshly prepared by dilution of a stock solution of  
1 M ammonium acetate and 0.1 M acetic acid solution in the appropriate volume of solvents. 
3.2. Phospholipid Standards 
Standards of PC(18:0/18:1) (1-stearoyl-2-oleoyl-sn-glycero-3-phosphocholine) (Mr 787.6091 Da), 
PC(16:0/14:0) (1-palmitoyl-2-myristoyl-sn-glycero-3-phosphocholine) (Mr 705.5308 Da), PE(18:0/18:1) 
(1-stearoyl-2-oleoyl-sn-glycero-3-phosphoethanolamine) (Mr 745.5621 Da) and PE(16:0/18:1)   
(1-palmitoyl-2-oleoyl-sn-glycero-3-phosphoethanolamine) (Mr 717.5308 Da) were purchased from 
Avanti Polar Lipids, Alabaster, AL, USA. All phospholipid standard solutions were prepared at a 
concentration of 25 mg/mL in MeOH/CHCl3 (50:50 v/v) and stored at a temperature of −20 °C. 
3.3. Xenografts 
Human breast cancer cells (MDA-MB-231, MDA-MB-435 and MCF-7) were cultured in 
Dulbecco’s Modified Eagle’s Medium (DMEM) supplemented with 10% fetal bovin serum (FBS),  
L-Glutamine (2 mM), penicillin (100 U/mL) and streptomycin (100 μg/mL) at 37 °C in a 5% CO2 
humid atmosphere. All culture reagents were purchased from Gibco-Life Technologies (Invitrogen, 
Paisley, UK). For in vivo injection, subconfluent cells were trypsinized, resuspended in serum-free 
medium (5 × 10
6 cells/mL) and mixed with an equal volume of cold Matrigel. Cell suspension   
(10
6 cells/400 μL) was injected s.c. in both flanks of 6-month-old recombination Activating Gene 
RAG
−/− mice (provided by the Central Animal Housing of Liège University, Liège, Belgium).   
Note that all animal procedures were performed according to the Federation of European Laboratory 
Animal Sciences Associations (FELASA) and local ethical committee at University of Liege 
(Belgium). Animals were housed within the accredited animal facility of GIGA located at the   
CHU-Sart Tilman (University of Liege, Liege, Belgium). 
Five to six weeks post-injection, mice were sacrificed and the tumors were resected and snap frozen 
by immersion in pre-cooled isopentane at −80 °C for 1 min. Tumors were kept at −80 °C until use. 
3.4. Tissue Preparation and Immunochemistry 
Tissue sections were prepared using a Research Cryostat Leica CM3050 S (Leica Microsystems 
Wetzlar, Germany) with the microtome chamber chilled at −25 °C and the specimen holder at −15 °C, Int. J. Mol. Sci. 2013, 14 24572 
 
cryostat sections of 14 μm thick were mounted onto ITO-coated microscopic slides (Bruker Daltonics, 
Bremen, Germany) adapted for MALDI mass spectrometry and dried 2 h in a desiccator. 
The following protocol for hematoxylin and eosin (H&E) staining was performed: (1) rehydrate in 
100% and 95% EtOH (2 min each), (2) rinse in H2O (10 s), (3) stain in hematoxylin   
(CAT Hematoxylin) (3 min), (4) rince in tap H2O (10 s), (5) rince in 70% EtOH/1% HCl (20 s),  
(6) rince in H2O (15 min), (7) dehydrate in 95% EtOH (1 min), (8) counterstain in eosin (EDGAR 
DEGAS Eosin) (2 min), (9) rince and dehydrate in 95% EtOH (20 s), (10) rince and dehydrate again in 
100% EtOH (20 s) and (11) dip in xylene (40 s). Sections were dried at room temperature in a hood 
and mounted with EUKITT (Kindler GmbH, Ziegelhofstrasse, Freiburg, Germany). 
Immunostainings were performed with a mouse monoclonal anti-human-Ki-67 (DakoCytomation, 
Glostrup, Denmark) for proliferating tumor cells, a rat anti-CD45 coupled to biotin (BD Biosciences, 
Tennessee, CA, USA) for inflammatory cell and a rabbit anti-carbonic anhydrase IX   
(Abcam, Cambridge, UK) for hypoxia. Frozen sections were fixed in formol solution (4%) or in 
paraformaldehyde (PAF 4% at 4 °C) for anti-CD45 antibody. For antigen retrieval, sections were 
incubated 10 min in Triton/PBS solution (0.1%). After, endogenous peroxidase activity was blocked 
with H2O2 3% (DakoCytomation), nonspecific binding was prevented by incubation of slides in 
PBS/BSA 10% (Fraction V, Acros Organics, NJ, USA) for 1 h for Ki 67 antibody and 30 min in 
normal swine serum (Fraction V, Acros Organics) for carbonic anhydrase IX antibody. Universal 
blocking reagent 10% (Biogenex HK085-5KE, Fremont, CA, USA) was used for sections stained with 
rat anti CD45/biotin. 
Ki-67 labeling was performed by a 1 h incubation with antibody (1:500) raised against the human 
protein and revealed with the power vision poly-HRP anti-Mouse/Rabbit/Rat IgG kit (1/100, 
DakoCytomation). For carbonic anhydrase staining, slides were incubated overnight with antibodies 
(1:1000, diluted in PBS/Normal Goat Serum) at 4 °C and with the power vision poly-HRP   
anti-Mouse/Rabbit/Rat IgG kit (1/100, DakoCytomation). Slides were revealed with Vector DAB   
(SK-4100, Vector Laboratories, Burlingame, CA, USA). 
For CD45 staining, slides were incubated with rat anti-CD45/biotin (BD Biosciences)   
(1:1500, diluted in PBS/BSA) overnight at 4 °C and incubated with the streptavidin poly-HRP kit 
(1/500, DakoCytomation, Glostrup, Denmark) for 30 min. 
Virtual images were acquired with the fully automated digital microscopy system dotSlide 
(Olympus, BX51TF, Aartselaar, Belgium) coupled with a Peltier-cooled high resolution digital color 
camera (1376 × 1032 pixels) (Olympus, XC10, Aartselaar, Belgium). Digital images of the whole 
tissue sections were digitized at high magnification (60×) producing virtual images in which the pixel 
size is 10 μm. Image processing was performed using image analysis tool box of MATLAB 9.2 
software (Matworks, Natick, MA, USA). In order to increase the contrast between the selected and 
surrounding regions, the excess of red component on images (two times red value minus blue value 
minus green value) was calculated. Int. J. Mol. Sci. 2013, 14 24573 
 
3.5. MALDI Fourier Transform-Ion Cyclotron Resonance MSI Analyses 
3.5.1. Matrix Deposition 
1,5-DAN deposition was performed in a homemade sublimation apparatus as previously described [28]. 
In the bottom of the sublimation apparatus 300 mg of 1,5-DAN matrix was deposited. Protocol was 
optimized for a fixed vacuum of 25 mTorr, monitoring temperature (150 °C), time of application  
(5 min), target plate temperature (14 °C) to ensure a homogeneous matrix coating. 
3.5.2. Mass Spectrometry 
Mass spectra were acquired using a SolariX Fourier transform mass spectrometer (FTMS) (9.4 T) 
equipped with an ESI/MALDI Dual Ion Source including Smartbeam
TM II laser (BrukerDaltonics, 
Bremen, Germany). Images were acquired with a pixel step size for the surface raster set to 80 μm 
with FlexImaging 3.0 software (Bruker Daltonics, Bremen, Germany). Mass spectra were externally 
calibrated using a phospholipid standards solution (PC(18:0/18:1)/PC(16:0/14:0)/PE(18:0/18:1)/ 
PE(16:0/18:1); 1:1:1:1 v/v/v/v). MALDI lipid mass spectra were acquired in positive ion mode from 
100 laser shots that accumulated at each spot. The laser power was set to 18% with a frequency of 
1000 Hz. For broadband detection mode analyses, mass range was set to m/z 100–1500 and time of 
flight value was 7 ms. Q1 mass was fixed at m/z 750 to focus on PL species, also taking into account 
other lipid species that can be detected during tissue MS analysis. Ion cooling time was set to 0.01 s. 
For narrowband detection mode analyses, center mass was set to m/z 745 ± 50 and time of flight value 
was 0.001 ms. For phospholipid molecular formula determination, monoisotopic masses from acquired 
mass spectra selected from images acquired from tumor sections were labeled using DataAnalysis 4.0 
software (Bruker Daltonics, Bremen, Germany) with the FTMS peak-picking algorithm according to 
default parameters. Molecular formulas were determined manually using the SmartFormula algorithm 
in DataAnalysis 4.0 (Bruker Daltonics, Bremen, Germany). Tolerance was set to 1 ppm. Phospholipid 
identification was done by searches against “LIPID Metabolites and Pathways Strategy”   
(Lipid Maps) database (website: http://www.lipidmaps.org/) [58]. Identifications were performed by  
“Text-based searches” using experimental monoisotopic masses of each low-abundant PL species. 
Mass tolerance was set to ±0.01 Da. Molecular formulas were confirmed from ones determined with  
SmartFormula algorithm. 
3.6. Probabilistic Latent Semantic Analysis 
pLSA were carried out using ClinPro Tools 3.0 software (Bruker Daltonics, Bremen, Germany). 
Mass spectra from narrowband detection mode analyses of MCF-7, MDA-MB-231 and MDA-MB-435 
samples were imported into ClinPro Tools 3.0 software. Normalization, peak peaking and spectra 
internal recalibration were automatically performed using the software. An average mass spectrum 
created from all single spectra was used for peak selection. Int. J. Mol. Sci. 2013, 14 24574 
 
3.7. LC-ESI-MS Analyses 
3.7.1. Phospholipid Standard Preparations 
Before injection in the High Performance Liquid Chromatography (HPLC) (Agilent, Waldbronn, 
Germany) column, each phospholipid standard (10 μL) was mixed in 160 μL of a solution composed 
of 40% mobile phase (B) and 60% mobile phase (A). 
3.7.2. Lipid Extraction from MDA-MB-231, MDA-MB-435, and MCF-7 Tumors 
Lipids were extracted according to the Folch et al. method [59]. Amounts of 100 mg of each tumor 
were homogenized in MeOH/CHCl3 (2:1 v/v) to a final dilution 20-fold the volume of the tissue 
sample. After homogenization, mixtures were agitated during 50 s at 3000 g in a MagNaLyser 
Instrument (Roche, Basel, Switzerland) at room temperature (RT) and stored at 4 °C for 5 min. This 
step was repeated twice. Samples were then centrifuged (50 s at 3500 g at RT) to recover the liquid 
phase. The supernatant was washed with 0.2 volumes of H2O milliQ and briefly vortexed. The final 
biphasic mixtures were centrifuged (10 min, 2000 g) and the upper aqueous phase discarded.   
The lower chloroform phase of each sample was evaporated under vacuum in a SPD121Savant 
SpeedVac rotary evaporator (Thermo Electron Corporation, Waltham, MA, USA). Following the 
Folch extraction, 50 mg of each dry sample was recovered. Samples were then dissolved in 500 μL of 
a mixture of MeOH/CHCl3 (50:50 v/v). Each lipid extract (20 μL) was dissolved in 180 μL of a 
mixture of 40% of mobile phase (B), 60% of mobile phase (A) for LC-ESI-MS analyses. 
3.7.3. LC-ESI-MS Analyses 
Phospholipid separation and identification were performed using the method published by   
Uhl et al. [51] with modifications. The HPLC system was an Agilent 1100 (Agilent Technologies, 
Takakuramachi, Japan) series equipped with a quaternary HPLC pump and an on-line membrane 
degasser. For the autosampler, we employed the standard Agilent autosampler Automatic Liquid 
Sampler (ALS) using the 100 vials system and a 100 μL variable volume sampling loop with a 
thermostat system set at 6 °C. The column oven was also available and the temperature oven was fixed 
at 60 °C. The RP-HPLC column was a C18 Xbridge column of 4.6 mm × 150 mm × 3.5 μm from 
Waters (Waters, Milford, MA, England). The mass spectrometer was a LTQ FTICR Ultra   
(Thermo Finnigan, Waltham, MA, USA), a hybrid mass spectrometer using a linear quadrupole ion 
trap and an Ion Cyclotron Resonance (ICR) mass analyzer (7 T magnet). The ion source was the  
Ion Max electrospray source operating in positive mode. The instrument was first tuned using   
the recommendation of the manufacturer. Then ion optic was optimized by direct infusion of   
the phospholipid standards. The Fourier Transform mass spectrometer (FTMS) was mass calibrated 
using some phosphoric acid solution at 0.1% in solution in 50% acetonitrile (Sigma-Aldrich, St. Louis, 
MO, USA). 
A sample (20 μL) was injected for each LC-ESI-MS acquisition. The needle was rinsed using a mix 
of 90% (B) and 10% (A) after injection. The flow rate of the mobile phase was 0.8 mL/min.   
The elution program was first 40% of (B) over 4 min. Then the proportion of (B) was linearly Int. J. Mol. Sci. 2013, 14 24575 
 
increased until 70% over 6 min, then the proportion of (B) was slowly increased to achieve 99% using 
a linear gradient over 25 min and maintained for 6 min. Finally the proportion of (B) was linearly 
decreased to 40% in 1 min and maintained for 8 min before a new injection. A new sample could be 
injected after 50 min. A blank sample was periodically injected between each sample. The outlet of the 
HPLC column was connected to the source of the mass spectrometer. A micro-splitter (Supelco,   
Sigma-Aldrich) was used in order to obtain a flow rate of 60 μL/min entering the ESI source of the 
mass spectrometer. The ESI source voltage was +2.0 kV, the sheath gas flow was fixed to 50   
(arbitrary unit). The temperature of the transfer capillary was set to 220 °C where a voltage of 17 V 
was applied. The tube lens voltage was fixed to 70 V. The ion optic was set using the following values: 
Multipole off set 00: −4.25 V; Lens 0 voltage: −4.0 V; Multipole: −4.75 V, Lens 1: −9.0 V; Gate lens: 
−78 V; multipole 1: −7.0 V; Multipole RF: 400 Vpp and Front lens: −5.25 V. A 50 min segment 
composed of nine event scans was used. The first event scan was a fullscan spectrum over a mass 
range of m/z 100–1000 using the linear quadrupole ion trap MS. The maximum filling time was fixed 
to 200 ms and five microscans were used. The second scan event was similar to the first scan event 
except that FTMS was used. The resolution was set to 25,000 and the maximum filling time was fixed 
to 200 ms. The FTMS scan event maximum duration was about 2.5 s. The four next scan events were 
MS/MS experiments using Collision Induced Dissociation (CID) ion activation at m/z ratios 744.5, 
766.5, 790.5 and 796.5 using a selection window mass range of 2 Th and normalized collision energy 
of 25%. The mass ranges for these spectra were about m/z 170–1000. For this purpose, the Act Q was 
fixed to 0.20 and the act time was fixed to 30 ms. Xcalibur v2.0.7 (Thermo Fisher Scientific) was used 
for data acquisition and processing. The mass spectra were recalibrated off line on the basis of the 
PC(18:0/18:2) mass observed in each lipid extract. PC(18:0/18:2) is an ubiquitous PL and notably 
detected in all analyzed tissues by LC/MS (i.e., MCF7, MDA-MB-231 and MDA-MB-435 xenografts, 
data not shown) and MALDI MSI (as example in Figures S10A,B for MCF7 and MDA-MB-435 
tumor sections, respectively). Relative PL abundance was estimated by comparing the intensity of an 
ion of interest (i.e., m/z 744.49419, 744.55385 and 744.59019 from LC-ESI-MS analyses of MCF-7 
and MDA-MB-435 tumor sections, Table S3) with the intensity of the most abundant ion observed in 
the base peak chromatogram. The PLs of interest were found to have less than 1% abundance 
compared to the most abundant species (i.e., eXtract Ion Chromatograms (XIC) ranged from m/z 
values 744.5 to 744.6 from LC-ESI-MS analyses of MCF-7, MDA-MB-231 and MDA-MB-435   
tumor sections, Figure S7). 
4. Conclusions 
Histochemical analyses of human xenograft tissue sections combined with high mass resolution 
MALDI MSI brings a real advantage in lipidomics by allowing the characterization of low-abundant 
PL species and their localization in regions of biological relevance such as necrosis, inflammation and 
proliferating tumor cells. Moreover, the targeted analysis of the lipid total extracts by LC-ESI-MS 
guided by MALDI MSI allows a complementary identification of the minor PL markers. So far, the 
involvement of these low PLs in biological signaling processes has been overlooked due to technical 
limitations. Our study provides the first visualization and characterization of minor phospholipids in 
human breast tumor xenograft models. This innovative combination of methods paves the way for Int. J. Mol. Sci. 2013, 14 24576 
 
future comprehensive analyses of low-abundant lipids in various types of tissues and will enlighten 
processes occurring during tumor growth and death, survival and the inflammatory process. Local 
extraction of lipids for further HPLC-MS measurements on regions of interest will be the next step 
thereby allowing quantification. 
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